Skip to main content

Table 1 Patient characteristics and treatment parameters

From: Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Variable SRS and ipilimumab SRS and nivolumab  
N = 45 N = 35 p
Sex (F/M) 17/28 14/21 1.0
Age (years)
 median 54 56 0.2
 range 23–78 26–80  
KPS    0.8
 median 80 80  
 60–70 13 9  
 80–100 32 26  
BRAF mutation    0.8
 present 15 13  
 absent 30 22  
 undetermined    
Extracranial disease    0.7
 present 34 25  
 absent 11 10  
Number of metastases   0.4
 single 8 9  
 multiple 37 26  
DS-GPA    0.3
 0–1 9 6  
 1.5–2.5 22 16  
 3–4 14 13  
Type of SRS    0.76
 Single-fraction SRS 153 132  
 Fractionated SRS 22 19  
Size of metastases    0.8
  < 2 cm 99 84  
 2–3 cm 46 38  
  ≥ 3 cm 30 29  
Total tumor volume (cm 3 )    0.1
 median 7.4 9.2  
 range 0.5–33.1 0.7–33  
GTV (cm 3 )    0.6
 median 1.12 1.2  
 range 0.05–27.9 0.4–31.2  
PTV (cm 3 )    0.3
 median 1.71 1.83  
 range 0.1–39.1 0.09–42.6  
Conformity index a    0.5
 median 1.43 1.41  
 range 1.10–1.91 1.12–1.85  
  1. SRS stereotactic radiosurgery, KPS Karnofsky Performance Status
  2. DS-GPA Diagnosis-Specific Graded Prognostic Factors, GTV Gross Target Volume
  3. PTV Planning Target Volume, acalculated as prescribed isodose volume/tumor volume
  4. encompassed by the prescription isodose volume